Absence of CHRFAM7A expression in COVID-19 patients was associated with some increased inflammatory biological markers and COVID-19 severity (lymphopenia, elevated CRP, elevated plasma viral load) with extension of the pulmonary lesions and with enhanced expression of genes of the TNF signaling pathway. This evidence concerns the gene CHRFAM7A and lymphopenia.